Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 177-184

  Scoccianti, Chiara ^a,d   Vesin, Aurélien ^b   Martel, Ghislaine ^a   Olivier, Magali ^a   Brambilla, Elisabeth ^b   Timsit, Jean François ^b   Tavecchio, Luca ^f   Brambilla, Christian ^b,g   Field, John K ^e   Hainaut, Pierre ^a,c   Martinet, Y ^h   Thunnissen, E ⁱ   Snijders, P ^j   Sozzi, G ^k   Risch, A ^l   Elborn, S ^m   Montuenga, L M ⁿ   O'Byrne, K ^o   Harrison, D J ^p   Niklinski, J ^q  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b INSTITUT ALBERT BONNIOT   (France)

^c INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g INSERM   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Istituto Nazionale Milan   (Italy)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m BELFAST CITY HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF NAVARRA   (Spain)

^o ST JAMES S HOSPITAL   (Ireland)

^p UNIVERSITY OF EDINBURGH   (United Kingdom)

^q MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

more..

Author keywords

EGFR; KRAS; Mutations; Nonsmall cell lung cancer; Prognosis; TP53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; DNA EXTRACTION; EGFR GENE; EUROPE; EUROPEAN EARLY LUNG CANCER; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA; TP53 GENE;

EID: 84863486249     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00097311     Document Type: Article

References (21)

1. Jedrychowski W, Becher H, Wahrendorf J, et al. Effect of tobacco smoking on various histological types of lung cancer. J Cancer Res Clin Oncol 1992; 118: 276-282.
2. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435-7451. (Pubitemid 35305599)
3. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010; 10: 241-253.
4. Denissenko MF, Pao A, Tang MS, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspot in P53. Science 1996; 274: 430-432. (Pubitemid 26353359)
5. Hainaut P, Pfeifer GP. Patterns of p53 G>T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001; 22: 367-374. (Pubitemid 32203813)
6. Hussain SP, Amstad P, Raja K, et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in non-tumorous human lung. Cancer Res 2001; 61: 6350-6355. (Pubitemid 32783236)
7. Cassidy A, Balsan J, Vesin A, et al. Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multicentre case-control study in Europe. Eur J Cancer 2009; 45: 3047-3053.
8. Field JK, Liloglou T, Niaz A, et al. EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. Eur Respir J 2009; 34: 1477-1486.
9. Mounawar M, Mukeria A, Le Calvez F, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in nonsmall cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-5672. (Pubitemid 46984998)
10. Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005; 65: 5076-5083. (Pubitemid 40827316)
11. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311. (Pubitemid 39209661)
12. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005; 11: 232-241. (Pubitemid 40075800)
13. Fine J, Gray JR. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
14. COSMIC Database. www.sanger.ac.uk/genetics/CGP/cosmic/ Date last updated: March 28, 2012. Date last accessed: March 28, 2012.
15. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629. (Pubitemid 46744292)
16. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. JNCI 2005; 97: 339-346. (Pubitemid 40425952)
17. Yatabe1 Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007; 57: 233-244.
18. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009; 4: 22-29.
19. Voortman J, Goto A, Mendiboure J, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010; 70: 8288-8298.
20. Dumont P, Leu JI, Della Pietra AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-365. (Pubitemid 36278852)
21. Mechanic LE, Bowman ED, Welsh JA, et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. CEBP 2007; 16: 214-222. (Pubitemid 46383337)